S&C Advises Seagen in $43 Billion Acquisition by PfizerMarch 15, 2023
Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, has agreed to be acquired by Pfizer for an enterprise value of $43 billion. This transaction, announced March 13, will enable Pfizer and Seagen to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining Seagen's expertise in antibody-drug conjugate technology with Pfizer's global resources. The deal would be the largest-ever all-cash acquisition in the biopharmaceutical industry.
The S&C team advising Seagen includes Matt Hurd, Melissa Sawyer, Brad King, Michael Fronk, Alex Bavis, Rachel Weiss and Jin Lee. Matt Friestedt, Sarah Remmer Long and Julia Paranyuk are advising on executive compensation matters. Renata Hesse, Samantha Hynes, Karl Bock and Daniel Richardson are advising on U.S. antitrust matters. Michael Rosenthal, Kolja Ortmann and Penelope Bergkamp are advising on global competition matters. Rachel Yu and Grace Son are advising on intellectual property matters. Davis Wang, Anna Erickson and Alexei Owen are advising on tax matters. Eric Kadel and Manon Scales are advising on trade compliance matters. Matthew Brennan is advising on environmental matters.